Ratings by Stifel (Dara Azar)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/26/2026 | Summit Therapeutics plc | SMMT | Maintain | Buy (N/A) |
|
Details | ||
| 10/6/2026 | Immunome Inc. | IMNM | Maintain | Hold (Hold) |
|
Details | ||
| 9/30/2026 | Whitehawk Therapeutics | WHWK | New Coverage | Buy (N/A) |
3.73 (3.18) |
-14.75% | Details | |
| 9/30/2026 | Immunome Inc. | IMNM | New Coverage | Hold (N/A) |
21.89 (18.20) |
-16.86% | Details | |
| 9/29/2026 | Summit Therapeutics plc | SMMT | Maintain | Buy (N/A) |
|
Details | ||
| 8/21/2026 | Inhibrx Biosciences | INBX | Maintain | Buy (Buy) |
|
Details | ||
| 8/6/2026 | Enliven Therapeutics | ELVN | Maintain | Buy (N/A) |
|
Details | ||
| 7/24/2026 | Summit Therapeutics plc | SMMT | Maintain | Buy (N/A) |
|
Details | ||
| 7/1/2026 | Enliven Therapeutics | ELVN | Maintain | Buy (N/A) |
|
Details | ||
| 6/8/2026 | Enliven Therapeutics | ELVN | New Coverage | Buy (N/A) |
34.71 (41.91) |
20.74% | Details | |
| 6/2/2026 | Inhibrx Biosciences | INBX | Maintain | Buy (Buy) |
|
Details | ||
| 6/1/2026 | Summit Therapeutics plc | SMMT | Maintain | Buy (Buy) |
|
Details | ||
| 5/15/2026 | Inhibrx Biosciences | INBX | Maintain | Buy (N/A) |
|
Details | ||
| 4/22/2026 | Inhibrx Biosciences | INBX | Maintain | Buy (N/A) |
|
Details | ||
| 4/21/2026 | Summit Therapeutics plc | SMMT | Maintain | Buy (N/A) |
|
Details | ||
| 4/17/2026 | Inhibrx Biosciences | INBX | Maintain | Buy (Buy) |
|
Details | ||
| 4/7/2026 | Inhibrx Biosciences | INBX | New Coverage | Buy (N/A) |
63.72 (94.44) |
48.21% | Details | |
| 4/7/2026 | Summit Therapeutics plc | SMMT | New Coverage | Buy (N/A) |
18.69 (15.33) |
-17.98% | Details |
